Abstract

This meeting aims to develop our understanding of the potential of liquid biopsies. This includes to support early detection of cancer; as prognostic, pharmacodynamic and predictive biomarkers of treatment efficacy and resistance; and for patient monitoring, including of minimal residual disease for early identification of disease relapse. It will also explore how liquid biopsies can be incorporated in cancer patient management and how implementation of liquid biopsies can change clinical practice.